Kalle Saksela

University of Helsinki — Finland

Immunology and Microbiology · Life Sciences

49h-index11.9kcitations184works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(48), Monoclonal and Polyclonal Antibodies Research(42), CAR-T cell therapy research(24), RNA Interference and Gene Delivery(23), HIV/AIDS drug development and treatment(19)

Publications183 total

Supplementary Figure 4 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Supplementary Figure 15 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Supplementary Figure 14 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Supplementary Figure 8 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Supplementary Figure 7 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Supplementary Figure 5 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Data from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Supplementary Figure 13 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Supplementary Figure 9 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Supplementary Figure 6 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Supplementary Figure 1 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Supplementary Figure 3 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Supplementary Figure 11 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Construct sequences from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Supplementary Figure 10 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Supplementary Figure 12 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Supplementary Figure 2 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
2025Open Access
Sherpabodies—A Highly Versatile and Modular Scaffold for Biomedical Targeting
Biologics·2025Open Access
Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy
Cancer Research·2025· 2 citedOpen Access
Altered spike dynamics drives immune evasion of SARS-CoV-2
2024Open Access
page 1 of 10Next →

Frequent Co-authors

G. Herma Renkema(7), Aki Manninen(7), David Baltimore(5), Arūnas Kazlauskas(5), Kari Alitalo(4), Marita Hiipakka(4), Raul Andino(3), Bruce J. Mayer(3), Mark Harris(3), Iivari Kleino(3), Ralf Wagner(3), Chi‐Hon Lee(2), John Kuriyan(2), Perttu Permi(2), Satu Kärkkäinen(2), Tomi P. Mäkelä(2), Robert Winqvist(2), Miika Martikainen(2), Ari Hinkkanen(2), Derek A. Mann(2)